<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): January 3, 2009</B>



<P style="font-size: 24pt" align="center"><B>NEUROBIOLOGICAL TECHNOLOGIES,
INC.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>000-23280</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>94-3049219</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>2000 Powell Street, Suite
800, Emeryville, California<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>94608</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(510) 595-6000</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>NOT
APPLICABLE<BR>
</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>



<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>Item&nbsp;5.02. Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangement of Certain Officers.</B>

<P style="font-size: 10pt; text-indent: 3%" align="left">On January&nbsp;3,
2009, the Board of Directors (the &#8220;Board&#8221;) of Neurobiological
Technologies, Inc. (the &#8220;Company&#8221;) terminated the
employment of Paul E. Freiman as President and Chief Executive Officer of the
Company, effective December&nbsp;31, 2008. As reported in a Current Report on
Form 8-K dated June&nbsp;26, 2008, Mr.&nbsp;Freiman had previously informed the
Board of his intention to retire as President and Chief Executive Officer as of
December&nbsp;31, 2008. Mr.&nbsp;Freiman was re-elected by the stockholders
of the Company to a three-year term as a member of the Board at the Annual Meeting
of Stockholders on November 13, 2008, and he continues to serve as a member of the Board.

<P style="font-size: 10pt; text-indent: 3%" align="left">Also on
January&nbsp;3, 2009, the Board appointed a Special Committee consisting of
William A. Fletcher and John&nbsp;B.&nbsp;Stuppin to assist the Company&#8217;s
senior management team with selected strategic and operational matters, on an
as-needed basis pending the appointment of a chief executive officer.
Mr.&nbsp;Fletcher will serve as Chairman of the Special Committee.

<P style="font-size: 10pt" align="center"><B>SIGNATURE</B>

<P style="font-size: 10pt; text-indent: 3%" align="left">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.

<P style="font-size: 10pt" align="left">Dated: January&nbsp;7, 2009
&nbsp;

<P style="font-size: 10pt; margin-left: 45%" align="left">NEUROBIOLOGICAL
TECHNOLOGIES, INC.

<P style="font-size: 10pt; margin-left: 45%" align="left">By: <U><FONT
style="font-variant: small-caps">/s/ Matthew M. Loar</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Matthew M.
Loar<BR>
Vice President and Chief Financial Officer<BR>


<P style="font-size: 10pt" align="center">2

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c79211e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 6638}]
{"company-data": {"conformed-name": "NEUROBIOLOGICAL TECHNOLOGIES INC /CA/", "cik": "0000918112", "assigned-sic": "2836", "irs-number": "943049219", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-23280", "film-number": "09513192"}, "business-address": {"street1": "2000 POWELL STREET, SUITE 800", "city": "EMERYVILLE", "state": "CA", "zip": "94608", "phone": "510-595-6000"}, "mail-address": {"street1": "2000 POWELL STREET,  SUITE 800", "city": "EMERYVILLE", "state": "CA", "zip": "94608"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): January 3, 2009
NEUROBIOLOGICAL TECHNOLOGIES,
INC.
(Exact name of registrant as
specified in its charter)
Delaware
000-23280
94-3049219
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
2000 Powell Street, Suite
800, Emeryville, California
94608
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
(510) 595-6000
NOT
APPLICABLE
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangement of Certain Officers.
On January 3,
2009, the Board of Directors (the "Board") of Neurobiological
Technologies, Inc. (the "Company") terminated the
employment of Paul E. Freiman as President and Chief Executive Officer of the
Company, effective December 31, 2008. As reported in a Current Report on
Form 8-K dated June 26, 2008, Mr. Freiman had previously informed the
Board of his intention to retire as President and Chief Executive Officer as of
December 31, 2008. Mr. Freiman was re-elected by the stockholders
of the Company to a three-year term as a member of the Board at the Annual Meeting
of Stockholders on November 13, 2008, and he continues to serve as a member of the Board.
Also on
January 3, 2009, the Board appointed a Special Committee consisting of
William A. Fletcher and John B. Stuppin to assist the Company's
senior management team with selected strategic and operational matters, on an
as-needed basis pending the appointment of a chief executive officer.
Mr. Fletcher will serve as Chairman of the Special Committee.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
Dated: January 7, 2009
NEUROBIOLOGICAL
TECHNOLOGIES, INC.
By:
/s/ Matthew M. Loar
Matthew M.
Loar
Vice President and Chief Financial Officer
2